The partnership was signed by Noramco, a global leading producer of controlled substances for the pharmaceutical industry, and active pharmaceutical ingredientsā€™ manufacturer Ampac Fine Chemicals (AFC), possessing a cGMP facilities in the United States. It will regulate the production of US DEA controlled substances for use in the treatment of addiction, abuse prevention, cannabinoids for clinical indications, and for the treatment of attention deficit hyperactivity disorder (ADHD). According to the companies, Noramco will continue to be the marketer and will utilize AFC as the contract manufacturer to supplement existing Noramco capacity.